Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...

A group often forgotten about in the discussion of HIV – despite research pointing to an ongoing crisis – is Black women in ...

An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...

Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa “The arrivals of the first doses of lenacapavir ...

News Is Out hosts an online panel discussion with Gilead’s Choose U ambassadors sharing stories of resilience, empowerment ...

Citi Annual Global Healthcare Conference 2025 December 2, 2025 11:15 AM ESTCompany ParticipantsAndrew Dickinson - ...

Dec. 1 is World AIDS Day, but for the first time in decades, the federal government is not recognizing it. One metro Atlanta ...

Birmingham native Carlton V. Bell II is an artist who believes telling the stories of the most marginalized can heal ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as ...

South Africa, Eswatini and Zambia on Monday began administering a groundbreaking HIV-prevention injection in the drug's first ...